LB Pharmaceuticals (LBRX) vs OPKO Health (OPK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LB Pharmaceuticals (LBRX) has outperformed OPKO Health (OPK) over the past year, gaining 130.1% versus a loss of 11.6%. LB Pharmaceuticals is the larger company by market cap ($1.12 billion vs $1.02 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LBRX | OPK |
|---|---|---|
| Share price | $34.61 | $1.37 |
| Market cap | $1.12B | $1.02B |
| 1-day change | +1.32% | -1.44% |
| YTD return | +55.48% | +8.73% |
| 1-year return | +130.12% | -11.61% |
| 5-year return | — | -63.17% |
| P/E ratio (TTM) | 346.10 | — |
| EPS (TTM) | $0.10 | $-0.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.16 | $1.75 |
| 52-week low | $14.32 | $0.98 |
| Distance from 52-week high | -31.00% | -21.71% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +65.56% | +219.71% |
| Average volume | 341.17K | 3.35M |
| Shares outstanding | 32.26M | 746.33M |
| Employees | 49 | 2,275 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LBRX has outperformed OPK by 141.7 percentage points over the past year.
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About OPKO Health
OPK stock →OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,275 employees
LBRX vs OPK FAQ
Which is bigger, LB Pharmaceuticals or OPKO Health?
LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.12B compared with $1.02B for OPKO Health (OPK).
Which stock has performed better over the past year, LBRX or OPK?
LBRX returned +130.12% over the past 12 months, compared with -11.61% for OPK (price return, excluding dividends). Past performance does not predict future results.
Are LB Pharmaceuticals and OPKO Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.